Subject: Blockbuster News from MJTV Read All About it Here

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
Blockbuster News from MJTV Read All About it Here
Hot Stock to WatchHot Stock to Watch

Company: Michael James Enterprises, Inc. (OTCQB: MJTV)


Last:

Price: 0.13

Change (%): + 0.0 (0.0)

Volume: 0
MJTV Chart

Michael James Enterprises Signs Asset Purchase Agreement Acquiring All Rights and Intellectual Property for the Development of Dronabinol-Based Therapeutic Treatments for Sleep Disorders

SHORT HILLS, NJ-(Marketwired - Aug 5, 2016) - Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that MJTV has entered into an Asset Purchase Agreement with RP Capital Group acquiring all of the rights and intellectual property to develop and bring to market therapeutic treatments for sleep disorders using Dronabinol as the base ingredient. Raj Pamnani, who recently joined the Board of Directors, brings to MJTV this promising already work in progress therapeutic treatment.

Dronabinol is the generic form of Marinol, a cannabinoid that was approved by the FDA to be prescribed by doctors in all 50 states back in 1985. Currently Dronabinol is used for cancer patients for nausea and aids patients to help keep up their weight. The University of Illinois, Chicago recently finished phase 2B clinical trials to treat sleep apnea utilizing Dronabinol with the results to be published in the next few weeks. If the results are what everyone expects them to be, it will be a major moment for the potential expanded use of Dronabinol for sleep disorders.

Prior to bringing these rights into MJTV, Mr. Pamnani, added in another active ingredient with the Dronabinol and conducted pre-clinical trials with very promising results. We feel this is a major improvement for treating sleep apnea above using just Dronabinol. MJTV will be working on additional formulations with the Dronabinol for other medical indications and applications moving forward.

James Farinella, CEO of Michael James Enterprises stated, “I had originally planned to bring this product into MJTV but wanted to have the clinical 2B trials completed first. This was always expected to be the main business of MJTV. We will now keep the acne treatment system in the private company and advance the business and get it closer to commercialization before considering bringing it into the fold.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks